Меню
Набор скоро начнётся NCT07432854

A Clinical Study Evaluating the Efficacy and Safety of CMS-D001 Tablets in the Treatment of Adult Patients With Moderate to Severe Plaque-type Psoriasis

Фаза II / Фаза III С лечением Moderate to Severe Plaque Psoriasis

Ориентир для пациента и семьи

Простыми словами

Автоматическая сводка по структурированным данным реестра. Она помогает сориентироваться, но не заменяет официальный протокол или оценку врача.

Что изучают
В протоколе указаны: CMS-D001 50mg, CMS-D001 100mg, Placebo.
Кому может быть актуально
Состояния в реестре: Moderate to Severe Plaque Psoriasis. Базовые параметры: 18 лет — 75 лет · Все.
Что важно проверить
Возраст, диагноз и пол — только базовые ориентиры. Предыдущее лечение, анализы и другие обязательные условия указаны ниже в критериях участия.
Где проводится
Китай
Следующий шаг
Сохраните исследование, покажите его лечащему врачу и уточните актуальный статус у исследовательского центра. Расходы, документы и поездка →

Не всё понятно в терминах? Прочитайте наш гид для пациентов →

Официальное название

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase Ⅱ/Ⅲ Clinical Study to Evaluate the Efficacy and Safety of CMS-D001 Tablets in Adult Patients With Moderate to Severe Plaque Psoriasis

Обзор

This study adopted a multicenter, randomized, double-blind, placebo-controlled phase II/III operation seamless adaptive design, aiming to evaluate the efficacy, safety and tolerability of CMS-D001 tablets in the treatment of patients with moderate to severe plaque psoriasis. The trial consists of two parts, including the Phase II clinical research stage and the Phase III clinical research stage.

Подробное описание

In the Phase II clinical research stage, a multi-center, randomized, double-blind, placebo-controlled design will be adopted, with a planned enrollment of 120 participants. After providing written informed consent and completing all screening evaluations, eligible participants will be randomly assigned in a 1:1:1 ratio to Trial Group 1, Trial Group 2, and the placebo group, with 40 participants in each group.All randomly assigned participants will undergo a 12-week double-blind treatment and continue to be followed up until the 16th week. The study is divided into three phases: the screening period (up to 4 weeks), the treatment period (12 weeks, approximately 85 ± 3 days), and the follow-up period (2 weeks after the last dose).

In the Phase III clinical research stage, a multi-center, randomized, double-blind, placebo-controlled design will be adopted. It is planned to continue enrolling participants in the Phase III study after the completion of the Phase II clinical trial enrollment, based on the Phase II dose groups (or the recommended dose groups determined based on the Phase II study results) and the placebo group. A total of 420 participants are planned to be enrolled. After providing written informed consent and completing all screening evaluations, eligible participants will be randomly assigned in a 2:2:1 ratio to the CMS-D001 tablet 50 mg QD, 100 mg QD, and placebo control groups. Each treatment group will have a maximum of 168 participants (excluding those who switch from the placebo group), and the placebo group will have a maximum of 84 participants.The research was divided into 4 phases, namely the screening phase (up to 4 weeks), the base phase (16 weeks), the expansion phase (36 weeks), and the follow-up phase (4 weeks after the last administration).

Вмешательства

  • Препарат CMS-D001 50mg
    CMS-D001 50mg QD
  • Препарат CMS-D001 100mg
    CMS-D001 100mg QD
  • Препарат Placebo
    Placebo QD

Первичные конечные точки

  • Phase Ⅱ:Number of participants achieving at least 75% improvement in Psoriasis Area and Severity Index (PASI 75) [Срок оценки: At week 12]
  • Phase Ⅲ:Number of participants achieving at least 75% improvement in Psoriasis Area and Severity Index (PASI 75) [Срок оценки: At week 16]
  • Phase Ⅲ:Number of participants achieving a Physician Global Assessment (PGA) score of 0 (clear) or 1 (almost clear) (PGA-TS) [Срок оценки: At week 16]
Вторичные конечные точки (12)
  • PhaseⅡ:Number of participants achieving at least 75% improvement in Psoriasis Area and Severity Index (PASI 75) [Срок оценки: At week 2, 4, 8]
  • PhaseⅡ:Number of participants achieving a Physicians Global Assessment (PGA) score of 0 or 1. [Срок оценки: At week 2, 4, 8, 12]
  • PhaseⅡ:Number of participants achieving at least 50%, 90%, or 100% improvement in PASI (PASI 50/90/100) [Срок оценки: At week 2, 4, 8, 12]
  • PhaseⅡ:Change and percentage change from baseline in the Psoriasis Area and Severity Index (PASI) score. [Срок оценки: At week 2, 4, 8, 12]
  • PhaseⅡ:Change and percentage change in affected Body Surface Area (BSA) from baseline [Срок оценки: At week 2, 4, 8, 12]
  • PhaseⅡ:Change in Dermatology Life Quality Index (DLQI) score from baseline [Срок оценки: At week 2, 4, 8, 12]
  • Phase Ⅲ:Number of participants achieving at least 75% improvement in PASI (PASI 75) [Срок оценки: At weeks 2, 4, 8, 12 and at each visit in the extension period]
  • Phase Ⅲ:Number of participants achieving at least 90% or 100% improvement in PASI (PASI 90/100) [Срок оценки: At weeks 2, 4, 8, 12, 16 and at each visit in the extension period]
  • Phase Ⅲ:Number of participants achieving a Physician Global Assessment (PGA) score of 0 (clear) or 1 (almost clear) [Срок оценки: At weeks 2, 4, 8, 12 and at each visit in the extension period]
  • Phase Ⅲ:Change and percentage change in PASI score from baseline [Срок оценки: At weeks 2, 4, 8, 12, 16 and at each visit in the extension period]
  • Phase Ⅲ:Change and percentage change in affected Body Surface Area (BSA) from baseline [Срок оценки: At weeks 2, 4, 8, 12, 16 and at each visit in the extension period]
  • Phase Ⅲ:Change in Dermatology Life Quality Index (DLQI) score from baseline [Срок оценки: At weeks 2, 4, 8, 12, 16 and at each visit in the extension period]

Критерии участия

Критерии включения

  • Aged 18-75 years, willing to sign the ICF
  • Diagnosed with plaque psoriasis for at least 6 months prior to screening.
  • At screening and baseline, PASI score ≥ 12 points, BSA ≥ 10%, sPGA ≥ 3
  • Be eligible for phototherapy or systemic therapy.

Критерии исключения

  • Non-plaque psoriasis (ie, guttate, pustular, erythrodermic, or inverse psoriasis) within 3 months prior to baseline.
  • Other skin diseases at screening or baseline Drug-induced psoriasis.
  • History of severe herpes zoster or severe herpes simplex or current herpes simplex/zoster infection.
  • History of a serious bacterial, fungal, or viral infection requiring hospitalization or intravenous antimicrobial therapy within 3 months prior to the first dose.
  • History of a bacterial, fungal, or viral infection requiring oral antimicrobial therapy within 4 weeks prior to the first dose.
  • Active infection or acute illness within 7 days prior to the first dose. Chronic or recurrent infectious diseases at screening or baseline that, in the investigator's judgment, may increase safety risks.
  • Evidence of active TB. Patients with evidence of latent tuberculosis may enter the trial after sufficient treatment had initiated and maintained according to protocol.
  • History of a major or unstable clinical condition within 6 months prior to the first dose, which would compromise participation.
  • History of malignant tumour within 5 years before screening.
  • Previous or current autoimmune diseases.
  • Positive results of confirmatory test for hepatitis B, hepatitis C, human immunodeficiency virus (HIV) or syphilis.
  • Allergic to any component of the investigational drug.

Критерии приведены из реестра в оригинале (на английском). Окончательную оценку соответствия проводит исследовательский центр.

Здоровые добровольцы: Нет

Дизайн исследования

Распределение
Рандомизированное
Модель
Параллельные группы
Маскирование
Четверное слепое
Основная цель
Лечение

Центры проведения

Китай · 21 центр
  • The First Affiliated Hospital of Bengbu Medical College — Bengbu
  • The First Affiliated Hospital of Wannan Medical College (Yijishan) — Wuhu
  • Southern Medical University Dermatology Hospital — Гуанчжоу
  • Zhujiang Hospital of Southern Medical University — Гуанчжоу
  • Affiliated Hospital of Chengde Medical College — Chengde
  • Affiliated Hospital of Hebei University of Engineering — Handan
  • Shijiazhuang Traditional Chinese Medicine Hospital — Shijiazhuang
  • The Fourth Affiliated Hospital of Hebei Medical University — Shijiazhuang
  • … и ещё 13 центров

Идентификаторы

NCT: NCT07432854 · D001-02-002

Первоисточники (государственные реестры)

Открыть это исследование на ClinicalTrials.gov ↗